GlassScriptPhysician profile
John R Wooley
NPI 1174577944
$7,063.80
in general payments reported to CMS, 2019-2025
42 companies · $463 in 2025
The $463 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,048 · 2020: $686 · 2021: $955 · 2022: $592 · 2023: $790 · 2024: $530 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,329.67 | 2019-2020 | |
| Abbvie INC. | $665.30 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $521.14 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $368.34 | 2023-2025 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $308.31 | 2019-2021 | |
| Pfizer INC. | $262.35 | 2019-2025 | |
| Amgen INC. | $248.84 | 2019-2022 | |
| Coopersurgical, INC. | $237.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.22 | 2020-2023 | Trintellix |
| Shield Therapeutics INC | $170.62 | 2022-2024 | Accrufer |
| Astellas Pharma US INC | $146.12 | 2024-2025 | Veozah |
| Vertical Pharmaceuticals, LLC | $145.70 | 2019-2020 | |
| Gynesonics, INC. | $141.05 | 2021 | |
| Exeltis, USA INC. | $129.51 | 2020-2023 | Slynd |
| Hologic Sales and Service, LLC | $127.56 | 2023-2025 | Novasure, Myosure Tissue Removal Device |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.